Skip to main content

Table 1 Characteristics of the patients with bladder cancer

From: Development of a high-precision bladder hyperthermic intracavitary chemotherapy device for bladder cancer and pharmacokinetic study

 HIVEC+TUR (n = 128)HIVEC (n = 37)P
Age (years)50.7 ± 1.9 (37–66)51.6 ± 2.3 (39–66)0.07
Sex, n (%)
 Male86 (67.2)22 (59.5)0.09
 Female42 (32.8)15 (40.5)0.07
Disease course (days)11.4 ± 1.311.3 ± 1.60.07
Tumor location, n (%)
 Side wall35 (27.3)1 (2.7)0.06
 Posterior wall27 (21.1)2 (5.4)0.08
 Top area19 (14.8)1 (2.7)0.08
 Triangle area10 (7.8)17 (45.9)0.06
  ≥ two tumors37 (28.9)16 (43.2)0.07
Tumor size, n (%)
  ≥ 0.5 cm66 (51.6)28 (75.6)0.07
  < 0.5 cm62 (48.4)9 (24.4)0.09
Tumor stage, n (%)
 Tis13 (10.2)00.06
 T173 (57.0)9 (24.3)0.06
 T242 (32.8)28 (75.7)0.08
Tumor differentiation, n (%)
 G141 (32.0)11 (29.7)0.08
 G254 (42.2)14 (37.8)0.08
 G333 (25.8)12 (32.4)0.75
  1. HIVEC: bladder intracavitary hyperthermic perfusion chemotherapy